Hypercalcemia Treatment Market Size Is Anticipated To Reach US$ 28,060.0 Million at a CAGR of 11.7% By 2027 | Says, Coherent Market Insights

Excess parathyroid hormone (PTH) released by the parathyroid glands is the most common cause of high calcium blood levels. This can cause enlargement of one or more parathyroid glands. Denosumab is a humanized monoclonal antibody used in hypercalcemia treatment. It inhibits the receptor activator of nuclear factor-κB ligand (RANKL).

In 2018, the global hypercalcemia treatment market was valued at US$ 10,696.6 million and is expected to surpass US$ 28,060.0 million by 2027.

Global Hypercalcemia Treatment Market: Drivers

The most prominent cause of high calcium levels in the blood is multiple myeloma. Thus, a high incidence of multiple myeloma is estimated to drive the global hypercalcemia treatment market growth. For example, according to the American Cancer Society, around 32,270 new cases of multiple myeloma are expected to be diagnosed in 2020 in the U.S. (17,530 men and 14,740 women).

*The Download PDF brochure only consists of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3504

Furthermore, the availability of appropriate drug therapy alternatives to surgery are also expected to propel the market growth. Bisphosphonates normalize serum calcium levels in the blood in more than 70% of patients with hypercalcemia of malignancy within a period of 2 to 6 days of the treatment. Bisphosphonates significantly reduce skeletal-related events (SREs).

Global Hypercalcemia Treatment Market: Opportunities

Precise and definitive diagnosis of severe symptomatic hypercalcemia remains challenging. Etiological discussion of the non-malignant causes of parathyroid hormone-suppressed hypercalcemia can address the issue in this regard.

Global Hypercalcemia Treatment Market: Restraints

The distribution of hypercalcemia drugs has to face logistical challenges in terms of manufacturers finding suitable channels such as drug stores and independent pharmacies to stock these medicines. The above factor is expected to hinder the growth of the market.

Need a discount?
Note: *The discount is offered on the Standard Price of the report.

Request discount for this report @ https://www.coherentmarketinsights.com/insight/request-discount/3504

Key Takeaways:

In 2018, based on drug type, the bisphosphonates segment was estimated to account for US$ 7,306.2 million in terms of value. The segment is expected to witness a CAGR of 11.7% during the forecast period (2019 – 2017) and is expected to reach US$ 19,798.3 million by 2027. Bisphosphonates are the standard of care in the management of cancer-associated hypercalcemia. Bisphosphonates such as Zoledronic Acid, Clodronate, and others are commonly prescribed drugs for hypercalcemia management. High preference for these medicines is expected to propel the segment growth during the forecast period.

In 2018, based on the distribution channel, the hospital segment dominated the global hypercalcemia treatment market, accounting for 39.0% of market share in terms of value, followed by clinics and Independent Pharmacy and Drug Stores, respectively. Patients go to the hospital mainly for the treatment of diseases like hyperkalemia. Furthermore, hospitals treat many cancer patients who may also be suffering from hypercalcemia. These above-mentioned factors are expected to propel the segment growth during the forecast period.

In 2018, the North America dominated the global hypercalcemia treatment market, accounting for 45.5% of the market share in terms of value, followed by Europe. Factors such as the presence of leading manufacturers, favorable reimbursement, and high patient population are also expected to propel the growth of the region during the forecast period.

Browse Press Release: https://www.coherentmarketinsights.com/press-release/hypercalcemia-treatment-market-2830

Market Trends:

Synthetic implants can be used to detect hypercalcemia linked with cancer. For example, in May 2018, researchers at ETH Zurich (Switzerland) and the University of Basel (Switzerland) reported an early warning system that consists of an encapsulated gene network integrated into human body cells implanted under the skin, which monitor blood calcium levels.

Lithium can adversely impact the parathyroid glands and causes long term thyroid problems. Furthermore, lithium-induced hyperparathyroidism is expected to occur in women four times more than in men.

Global Hypercalcemia Treatment Market: Competitive Landscape

Major players operating in the global hypercalcemia treatment market are Bayer Pharma AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Cipla Inc., and XOMA Corporation.

Global Hypercalcemia Treatment Market: Key Development

January 2019: Teva Pharmaceutical Industries Limited announced that it has resolved its ongoing dispute with Amgen over Teva’s generic cinacalcet HCl product.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this Report@ https://www.coherentmarketinsights.com/insight/request-sample/3504

Segmentation

• By Product Type
  • Bisphosphonates
    • Clodronate
    • Etidronate
    • Ibandronate
    • Pamidronate
    • Zoledronic Acid
  • Calcitonin
  • Glucocorticoids
  • Denosumab
  • Calcimimetics

• By Distribution Channel
  • Hospitals
  • Clinics
  • Independent Pharmacy & Drug Stores

• By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.